BRAF and non-small cell lung carcinoma: Among these, CDx indications include non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions and EGFR exon 21 L858R alterations (for afatinib, gefitinib, or erlotinib); EGFR exon 20 T790M for osimertinib; ALK rearrangements (for alectinib, crizotinib, or ceritinib); and BRAF V600E (for dabrafenib in combination with trametinib).